Louise Rodino-Klapac

Title: The Innovative Contributions of Louise Rodino-Klapac

Introduction

Louise Rodino-Klapac is a prominent inventor based in Cambridge, MA (US). She has made significant contributions to the field of biotechnology, particularly in the development of therapies for muscular dystrophy. With a total of 3 patents to her name, her work has the potential to impact many lives.

Latest Patents

Rodino-Klapac's latest patents include groundbreaking research on adeno-associated virus antibodies and fragments thereof. This patent focuses on an isolated anti-AAV (adeno-associated virus) antibody or an antigen-binding fragment capable of specifically binding to an epitope of the AAVrh74 capsid protein. Another significant patent addresses the systemic delivery of an adeno-associated virus vector expressing gamma-sarcoglycan for the treatment of muscular dystrophy. This patent describes methods for treating muscular dystrophy by administering a recombinant AAV (rAAV) vector, which is crucial for expressing the gamma-sarcoglycan gene in patients.

Career Highlights

Louise Rodino-Klapac is currently associated with Sarepta Therapeutics, Inc., a company known for its innovative approaches to genetic medicine. Her work at Sarepta has positioned her as a key figure in the development of therapies aimed at treating rare genetic disorders.

Collaborations

Rodino-Klapac collaborates with talented individuals in her field, including Sohrab Khan and Danielle Griffin. These collaborations enhance the research and development efforts at Sarepta Therapeutics, Inc.

Conclusion

Louise Rodino-Klapac's contributions to biotechnology and her innovative patents are paving the way for advancements in the treatment of muscular dystrophy. Her work exemplifies the impact that dedicated inventors can have on healthcare and medical research.